MX2008011473A - El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica. - Google Patents
El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica.Info
- Publication number
- MX2008011473A MX2008011473A MX2008011473A MX2008011473A MX2008011473A MX 2008011473 A MX2008011473 A MX 2008011473A MX 2008011473 A MX2008011473 A MX 2008011473A MX 2008011473 A MX2008011473 A MX 2008011473A MX 2008011473 A MX2008011473 A MX 2008011473A
- Authority
- MX
- Mexico
- Prior art keywords
- msh
- nicotine
- analogues
- precursors
- derivatives
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title abstract 3
- 229960002715 nicotine Drugs 0.000 title abstract 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract 3
- 239000002243 precursor Substances 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000000069 prophylactic effect Effects 0.000 title abstract 2
- 208000037273 Pathologic Processes Diseases 0.000 title 1
- WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 title 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 abstract 1
- 229930182566 Gentamicin Natural products 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 230000001754 anti-pyretic effect Effects 0.000 abstract 1
- 239000002221 antipyretic Substances 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 230000008105 immune reaction Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 229960005489 paracetamol Drugs 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2008011473A MX2008011473A (es) | 2006-05-08 | 2008-09-08 | El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2006/000031 WO2007129879A1 (es) | 2006-05-08 | 2006-05-08 | EL USO DE LA NICOTINA, SUS ANÁLOGOS, SUS PRECURSORES O SUS DERIVADOS EN EL TRATAMIENTO DE DIVERSOS PROCESOS PATOLÓGICOS SUSCEPTIBLES DE MEJORAR CON α-MSH ADMINISTRADA EN FORMA PROFILÁCTICA O TERAPÉUTICA. |
| MX2008011473A MX2008011473A (es) | 2006-05-08 | 2008-09-08 | El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008011473A true MX2008011473A (es) | 2008-09-24 |
Family
ID=38667940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008011473A MX2008011473A (es) | 2006-05-08 | 2008-09-08 | El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica. |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20090197921A1 (enExample) |
| EP (4) | EP2801360B1 (enExample) |
| JP (1) | JP2009536193A (enExample) |
| KR (1) | KR20130116374A (enExample) |
| CN (1) | CN101437515B (enExample) |
| AU (1) | AU2006343439B2 (enExample) |
| BR (1) | BRPI0621650A2 (enExample) |
| CA (1) | CA2651580C (enExample) |
| DK (1) | DK2801360T3 (enExample) |
| ES (1) | ES2683323T3 (enExample) |
| MX (1) | MX2008011473A (enExample) |
| NZ (1) | NZ572366A (enExample) |
| WO (1) | WO2007129879A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557804B2 (en) | 2002-03-25 | 2013-10-15 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US8039459B2 (en) | 2004-07-15 | 2011-10-18 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US20110206642A1 (en) * | 2009-10-15 | 2011-08-25 | Cohava Gelber | Preventing obesity-related metabolic syndrome with melagonesis |
| US9668969B1 (en) | 2012-02-22 | 2017-06-06 | Arturo Solis Herrera | Methods of using QIAPINE |
| WO2016038441A1 (en) | 2014-09-09 | 2016-03-17 | Arturo Solis Herrera | Methods for treating and preventing ocular diseases, disorders, and conditions with melanin and melanin analogs, precursors, and derivatives |
| HK1258883A1 (zh) | 2016-04-12 | 2019-11-22 | A‧索利斯‧赫雷拉 | 用烟硷乙酰胆硷受体激动剂治疗鼻和鼻旁粘膜病症的组合物和方法 |
| LU101520B1 (en) * | 2019-12-02 | 2021-06-07 | Herrera Arturo Solis | (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| US6610713B2 (en) * | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| CA2341952A1 (en) * | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| AU2005225458B2 (en) * | 2004-03-25 | 2008-12-04 | The Feinstein Institutes For Medical Research | Neural tourniquet |
-
2006
- 2006-05-08 ES ES14170573.1T patent/ES2683323T3/es active Active
- 2006-05-08 JP JP2009509455A patent/JP2009536193A/ja active Pending
- 2006-05-08 DK DK14170573.1T patent/DK2801360T3/en active
- 2006-05-08 WO PCT/MX2006/000031 patent/WO2007129879A1/es not_active Ceased
- 2006-05-08 CN CN200680054519.1A patent/CN101437515B/zh not_active Expired - Fee Related
- 2006-05-08 AU AU2006343439A patent/AU2006343439B2/en active Active
- 2006-05-08 EP EP14170573.1A patent/EP2801360B1/en active Active
- 2006-05-08 CA CA2651580A patent/CA2651580C/en active Active
- 2006-05-08 EP EP14170571.5A patent/EP2801358A3/en not_active Withdrawn
- 2006-05-08 KR KR1020137025038A patent/KR20130116374A/ko not_active Withdrawn
- 2006-05-08 BR BRPI0621650-1A patent/BRPI0621650A2/pt not_active Application Discontinuation
- 2006-05-08 EP EP06747531A patent/EP2027860A1/en not_active Ceased
- 2006-05-08 NZ NZ572366A patent/NZ572366A/en not_active IP Right Cessation
- 2006-05-08 EP EP20140170572 patent/EP2801359A3/en not_active Withdrawn
-
2008
- 2008-09-08 MX MX2008011473A patent/MX2008011473A/es active IP Right Grant
-
2009
- 2009-04-06 US US12/418,993 patent/US20090197921A1/en not_active Abandoned
-
2012
- 2012-06-27 US US13/534,710 patent/US20120270907A1/en not_active Abandoned
-
2015
- 2015-09-22 US US14/860,973 patent/US20160008347A1/en not_active Abandoned
-
2016
- 2016-06-08 US US15/176,555 patent/US20160279116A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ572366A (en) | 2012-02-24 |
| EP2801358A3 (en) | 2015-03-04 |
| US20090197921A1 (en) | 2009-08-06 |
| CN101437515B (zh) | 2016-04-20 |
| US20160008347A1 (en) | 2016-01-14 |
| BRPI0621650A2 (pt) | 2011-12-20 |
| CA2651580A1 (en) | 2007-11-15 |
| DK2801360T3 (en) | 2018-07-23 |
| EP2801360B1 (en) | 2018-04-25 |
| WO2007129879A1 (es) | 2007-11-15 |
| ES2683323T3 (es) | 2018-09-26 |
| US20120270907A1 (en) | 2012-10-25 |
| CN101437515A (zh) | 2009-05-20 |
| EP2801360A2 (en) | 2014-11-12 |
| EP2801359A3 (en) | 2015-05-06 |
| JP2009536193A (ja) | 2009-10-08 |
| KR20130116374A (ko) | 2013-10-23 |
| EP2801359A2 (en) | 2014-11-12 |
| EP2801360A3 (en) | 2015-03-04 |
| CA2651580C (en) | 2016-01-19 |
| US20160279116A1 (en) | 2016-09-29 |
| AU2006343439B2 (en) | 2013-05-16 |
| EP2801358A2 (en) | 2014-11-12 |
| AU2006343439A1 (en) | 2007-11-15 |
| EP2027860A1 (en) | 2009-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008011473A (es) | El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica. | |
| ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
| TN2011000209A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| MY142067A (en) | Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease | |
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| DE602006015851D1 (de) | Positive allosterische chinolon-m1-rezeptormodulatoren | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| MX2009003768A (es) | Metodos, compuestos, composiciones y vehiculos para suministrar el acido 3-amino-1-propanosulfonico. | |
| PL2526771T3 (pl) | Inhibitory kinazy tyrozynowej Brutona | |
| EA200971130A1 (ru) | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний | |
| BRPI0509340A (pt) | formulação compreendendo inibidores de histona desacetilase | |
| EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
| MX2012002583A (es) | Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1. | |
| TW200630327A (en) | Substituted phenylalkanoic acids | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| MX2023010328A (es) | Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso. | |
| ATE543507T1 (de) | Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| BRPI0619399B8 (pt) | derivado de metastina ou um sal do mesmo, e, medicamento | |
| ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
| EP1817312A4 (en) | MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| TW200621251A (en) | Substituted biaryl quinolin-4-ylamine analogues | |
| Zhou et al. | Design and synthesis of nanofibers of self-assembled de novo glycoconjugates towards mucosal lining restoration and anti-inflammatory drug delivery | |
| ES2525931T3 (es) | Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |